Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats

Epilepsy Research

Volumn 80, Issue 1, 2008, Pages 47-56

  Elwakkad, Amany S E ^a   El ElShamy, Karima A I ^a   Sibaii, H ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Fish oil; Propolis; Valproate

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; FISH OIL; MASTER; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROPOLIS; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; EPILEPSY; IMMUNITY; MALE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RAT;

EID: 44749094582     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2008.03.008     Document Type: Article

References (64)

1. Bhattacharya A., Rahman M., Banu J., Lawrence R.A., McGuff H.S., Garrent I.R., Fishbach M., and Fernandes G. Inhibition of osteoporosis in autoimmune disease prone MRL/MPj-Fas (lpr) mice by n-3 fatty acids. J. Am. Coll. Nutr. 24 (2005) 200-209
2. Boluk A., Guzelipek M., Savli H., Temel I., Ozisik H.I., and Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol. Res. 50 1 (2004) 93-97
3. Cavalheiro E.A., Leite J.B., Bortolotto Z.A., Turski W.A., Ikonomidou T., and Turski L. Long term effect of pilocarpine in rats structural damage of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia 32 (1991) 778-782
4. Cerdan C., Martin Y., Brailly H., Courcoul M., Flavetta S., Costello R., Mawas C., Birg F., and Olive D. Il-1 alpha is produced by T Lymphocytes activated via CD2 plus CD28 pathways. J Immunol. 146 2 (1991) 560-564
5. Chopra S., Pillai K.K., Husain S.Z., and Giri D.K. Propolis protects against doxorubicin-induced myocardiopathy in rats. Exp. Mol. Pathol. 62 (1996) 190-198
6. Clemens J.D., et al. Evidence that serum NTX (collagen-typ 1 N-telopeptides) can act as immunochemical marker of bone resorption. Clin. Chem. 43 (1997) 2058-2063
7. Dai S.M., Nishioka k, and Yudoh k. Interleukin-18 stimulates osteoclast formation through synovial T-cells in rheumatoid arthritis comparison with IL-1 beta and tumour necrosis factor-alpha. Ann. Rheum. Dis. 63 11 (2004) 1379-1386
8. Drezner M.K. Treatment of anticonvulsant drug induced bone disease. Epilepsy Behav. 5 Suppl. 2 (2004) S41-S47
9. Fernandes G., Lawrence R., and Sun D. Protective role of n-3 Lipids and soy protein in osteoporosis. Prostaglandins Leukot Essent fatty Acids 68 6 (2003) 361-372
10. Fulton J.P. New guidelines for the prevention and treatment of osteoporosis. National osteoporosis foundation. Med. Health R/82 (1999) 110-111
11. Grange J.M., and Davey R.W. Antibacterial properties of propolis. J. R. Soc. Med. 83 (1990) 159-160
12. Griel A.E., Kris-Etherton P.M., Hilpert K.F., Zhao G., West S.G., and Corwin R.L. An increase in dietary n-fatty acids decrease a marker of bone resorption in humans. Nutr. J. 6 (2007) 2 10.1186/1475-2891-6-2
13. Harvesteen B. Flavenoids, a class of natural products of high pharmacological potency. Biochem. Pharmacol. 32 (1983) 1141-1148
14. Hofbauer L.C., Gori F., Riggs B.L., Lacey D.L., Dunstan C.R., Spelsberg T.C., and Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid induced osteoporosis. Endocrinology 140 (1999) 4382-4389
15. Holick M.F., and Krane S.M. Introduction to bone and mineral metabolism. In: Eugene B., Fauci A., Kasper D., Hauser S., Longo D., and Jameson J.L. (Eds). Harrison's Principles of Internal Medicine. 15th ed. (2001), Mc Graw-Hill, New York 2192-2194
16. Holvoet S., Vincent C., Schimitt D., and Serres M. The inhibition of MAPK pathway is correlated with down regulation of MMP-9 secretion induced by TNF-alpha in human keratinocytes. Exp. Cell Res. 290 1 (2003) 106-119
17. Horwood N.J., Elliot J., Martin T.J., and Gillespie M.T. Osteoporotic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stomal cells. Endocrinology 139 (1998) 4743-4746
18. Jelńnska M., Tokarz A., Oledzka R., Czorniuk, and S'liwa A. Effects of dietary linseed, evening primose or fish oils on fatty acid and prostaglandin E2 contents in the rat livers and 7,12 dimethylbenz[a]anthracene-induced tumors. Biochem. Biophys. Acta 1637 (2003) 193-199
19. Kanzowa M., Sugimoto T., Kanatani M., and Chihara K. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cell. Eur. J. Endocrinol. 142 (2000) 661-664
20. Kim S.H., Lee J.W., Choi K.G., Chung H.W., and Lee H.W. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav. (2007) 13
21. Komine M., Kukita A., Kukita T., Ogata Y., Hotokebuchi T., and Kohashi O. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappa-B ligand in generation of osteoclasts in stromal cell depleted rate bone marrow cell culture. Bone 28 (2001) 474-483
22. Koyama N., Koschmieder S., Tyagi S., Nurnberger H., Wagner S., Bocker U., Hoelzer D., Gerhard Ottmann O., and Kalina U. Different effects of histone deacetylase inhibitors on Interleukin-18 gene expression in myeloid cells. Biochem. Biophys. Res. Commun. 292 4 (2002) 937-943
23. Kumandas S., Koklu E., Gumus H., Koklu S., Kurtoglu S., Karakukcu M., and Keskin M. Effect of carbamezapine and valproic acid on bone mineral density. IGF-I and IGFBP-3. J. Pediatr. Endocrinol. Metab. 19 4 (2006) 529-534
24. Lee S.K., and Lorenzo G.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast like cell formation. Endocrinology 140 (1999) 3552-3561
25. Lee K.W., Chun K.S., Lee J.S., Kang K.S., Surth Y.J., and Lee H.J. Inhibition of cyclooxygenase-2 expression and restoration junction intercellular communication in H-ras-transformed liver epithelial cells by caffeic acid phenethyl ester. Ann. N.Y. Acad. Sci. 1030 (2004) 501-507 (ISSN: 0077-8923)
26. Li Y., Seifert M.F., Ney D.M., Grahn M., Grant A.L., Allen K.G., and Watkins B.A. Dietary conjugated linoleic acid alters serum IGF-1 and IGF binding protein concentrations and reduces bone formation in rat fed (n-6) or (n-3) fatty acids. J. Bone Miner. Res. 14 (1999) 1153-1162
27. MÃrquez N., Sancho R., Macho A., Calzado M.A., Fiebich B.L., and Mu ñoz E. Caffeic acid phenethyl ester inhibits T-Cell activation by targeting both nuclear factor of activated T-cells and NF-Kappa B transcription factors. J. Pharmacol. Exp. Ther. 308 3 (2004) 993-1001 (ISSN: 0022-3565)
28. Masahiko W., Hishikawa K., Takayagani A., Shimizu N., and Nakaki T. Caffeic acid phenyl ester induce apoptosis by inhibition of NF Kß and activation of Fas in human breast cancer MCF-7 Cells. J. Biol. Chem. 279 7. (2004) 6017-6026
29. Michaluart P., Masferrer J.L., Caothers A.M., Subbaramaiah K., Zweifel B.S., Koboldt C., Mestre J.R., Grunberger d, Sacks P.G., Tanable T., and Dannenberg A.J. Inhibitory effects of caffeic acid phenethyl ester on the - and expression of cyclooxygenase-2 in human oral epithelial - and in a rat model of inflammation. Cancer Res. 59 10 (1999) 2347-2352 (ISSN: 0008-5472)
30. Nagata N., Kitaura H., Yoshida N., and Nakayama K. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T-Cell population (In process citation). Bone 33 4 (2003) 721-732 (ISSN: 8756-3282)
31. Nanes M.S. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology (Review) (182 refs). Gene 321 (2003) 1-15
32. Natarajan K., Singh S., Burke T.R., Grunberger Jr. D., and Aggrawal B.B. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-Kβ. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9090-9095 (1996 August Immunology)
33. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., and Pilbuam C.C. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast like cells in culture. J. Clin. Invest. 105 (2000) 823-832
34. Oner N., Kaya M., Karasalihoglu S., Karaca H., Cetik C., and Tutunculer F. Bone mineral metabolism changes in epileptic children receiving valproic acid. J. Paediatr. Child Health 40 8 (2004) 470-473
35. Orban Z., Mitsiades N., Burke T.R., Tsokos M., and Chrousos G.P. Caffeic acid phenethyl ester induces leucocyte apoptosis, modulates nuclear factor-kappa-B and suppresses acute inflammation. Neuroimmunomodulation 7 2 (2000) 99-105 (ISSN: 1021-7401)
36. Pack A.M. The association between antiepileptic drugs and bone disease. Epilepsy Curr. 3 3 (2003) 91-95
37. Pack A.M., Gidal B., and Vazquez B. Bone disease associated with antiepileptic drugs. Clev. Clin. J. Med. 71 Suppl. 2 (2004) 542-548
38. Price C.P. Multiple forms of human serum alkaline phosphatase: detection and quantitation. Ann. Clin. Biochem. 30 (1993) 355-372
39. Regina V., and Erich F.E. Interactions of different extracts of propolis with leukocytes and leukocytes enzymes. Drug Res. 46 (1996) 47-51
40. Sato Y., Kondo I., Ishida S., Motooka H., Takayama K., Tomita Y., Maeda H., and Satoh K. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57 3 (2001) 445-449
41. Schemer S. The Blood Morphology of Laboratory Animals. 3rd ed. (1967), Davi Co., Philadelphia p. 42
42. Scott R.A., Lhatoo S.D., and Sander J.W. The treatment of epilepsy in developing countries; where do we go from here?. Bull. World Health Organ. 79 (2001) 344-351
43. Seveberg L.R., Tauboll E., Isojärvi I.T., Pakarinen A.J., Huhtaniemi I.T., Knip M., and Gjerstad L. Effects of chronic valproate treatment on reproductive endocrine hormones in female and male Wister rats. Reprod. Toxicol. 16 (2002) 767-773
44. Sheth R.D. Metabolic concerns associated with antiepileptic medications. Neurology 63 (2004) S24-S29
45. Sheth, Weslowski C.A., Jacob J.C., Penny S., Hobbs G.R., Riggs J.E., and Bodensteiner J.B. Effect of carbamazapine and valproate on bone mineral density. J. Pediatr. 127 (1995) 256-262
46. Shin K.M., Kim I.T., Park Y.M., Choi J.W., Park H.J., Lee Y.S., and Lee K.T. Anti-inflammatory effect of caffeic acid methyl ester and mechanism of action through the inhibition of prostaglandin E2, nitric oxide and tumor necrosis factor -alpha production. Biochem. Pharmacol. 68 12 (2004) 2327-2336 (ISSN: 0006-2952)
47. Snedecor G.W., and Cochran W.G. Statistical Methods. 6th ed. (1967), The Lowa state University Press, Ames. Lowa, USA p. 104
48. Song X.O., Wang Z.P., Bas K.R., Zhang J.M., Wa S., Yan C.H., and Shen X.M. Effect of carbamazepine and valproate on bone metabolism in children with epilepsy. Epilepsy 43 10 (2005) 728-732
49. Sun D., Krishman A., Zamman K., Lawrence R., Battacharya A., and Fernandes G. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J. Bone Miner. Res. 18 (2003) 1206-1216
50. Sun L., Tamaki H., Ishimura T., Teruya T., Ohta Y., Katsuyama N., and Chinen I. Inhibition of osteoporosis due to restricted food intake by the fish oil DHA and EPA and perilla oil in the rat. Biosci. Biotechnol. Biochem. 68 12 (2004) 2613-2615 2003
51. Tang Q.Y., Kukita T., Ushijima Y., Kukita A., Nagata K., Sandra F., Watanabe T., Toh k., Okuma Y., Kawazaki S., Rasubala L., Teramachi J., Miyamoto I., Wu Z., and Lijima T. Regulation of osteoclastogenesis by Simon extracts composed of caffeic acid and related compounds: successful suppression of bone destruction accompanied with adjuvant-induced arthritis in rats. Histochem. Cell Biol. 125 3 (2006) 215-225 (ISSN: 0948-61430)
52. Trebble T.M., Stroud S.A., Calder P.C., Fine D.R., Mullee M.A., MonizC, and Arden N.K. High dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomized controlled trial. Br. J. Nutr. 94 (2005) 253-261
53. Turski W.A., Cavalheiro E.A., Bortolotto Z.A., Mello L.M., Schwarez M., and Turski L. Seizures produced by pilocarpine in mice: behavioral electroencephalographic and morphological analysis. Brain Res. 321 (1984) 237-253
54. Valsamis H.A., Arora S.K., Labban B., and McFarlane S.I. Antiepileptic drugs and bone metabolism. Nutr. Metab. 3 (2006) 36 10.1186/1743-7075-3-36
55. Voudris K., Moustaki M., Zeis P.M., Dimou S., Vagiakou E., Tsagris B., and Shardoutsou A. Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children receiving anticonvulsant monotherapy. Seizure 11 6 (2002) 377-380
56. Watkins B.A., Li Y., Allen K.G., Hoffman W.E., and Seifert M.F. Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. J. Nutr. 130 (2000) 2274-2284
57. Watkins B.A., Li Y., Lippman H.E., and Seifert M.F. Omega-3polyunsaturated fatty acids and skeletal health. Exp. Biol. Med. (Maywood) 226 (2001) 485-497
58. Watkins B.A., Li Y., and Seifert M.F. Nutraceutical fatty acids as biochemical and molecular modulators of skeletal biology. J. Am. Coll. Nutr. 20 5 (2001) 410S-416S
59. Watkins B.A., Li Y., Lippman H.E., and Feng S. Modulatory effect of omega-3 polysaturated fatty acids on osteoblast function and bone metabolism. Prostaglandins Leukot Essent Fatty Acids 68 (2003) 387-398
60. Williams Jope. Protein synthesis inhibitors attenuate seizures induced in rats by pilocarpine plus lithium. Exp. Neurol. 129 (1994) 169-173
61. Yildiz M., Cieck E., Cerci S.S., Cerci C., Oral B., and Koyu A. Influence of electromagnetic fields and protective effect - on bone mineral density in rats. Arch. Med. Res. 37 7 (2006) 818-821 (ISSN: 0188-4409)
62. Zeni S., Gomez-Acotto C., Di Gregorio S., and Mautalen C. Differences in bone turnover and skeletal response to thyroid hormone treatment between estrogen - depleted and replaced rats. Calcif. Tissue Int. 67 (2002) 173-177
63. Zhang Y.H., Heulsnann A., Tondravi M.M., Mukherjee A., and AbuAmer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL induced osteoclastogenesis via coupling of TNF type-1 receptor and RANK signaling pathways. J. Biol. Chem. 276 (2001) 563-568
64. Zou W., Hakim I., Tschoep K., Endres S., and Bar-Shavit Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J. Cell Biochem. 83 (2001) 70-83